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Abstract
Background: Chronic obstructive pulmonary disease (COPD) is a respiratory syndrome characterized by progressive,
partially reversible airway obstruction and lung hyperinflation. COPD has a substantial burden which is seen in both
patient quality of life and healthcare costs. One proposed method of minimizing this burden is the implementation
of clinical pathways (CPWs). CPWs aim to guide evidence-based practice and improve the interaction between
health services. They bring the best available evidence to a range of healthcare professionals by adapting evidence-
based clinical guidelines to a local context and detailing the essential steps in the assessment and care of patients.
Methods: The aim of this systematic review is to synthesize existing literature on the effects of CPWs for the
treatment or management of COPD. We will screen search hits from search strategies developed for a Cochrane
Effective Practice and Organisation of Care (EPOC) systematic review on the use of CPWs in primary care and a
Cochrane EPOC review on the use of CPWs in hospitals. These searches were run in a range of databases. Studies
will be screened independently by two reviewers. All studies identified by our search strategy will be considered
regardless of study design as long as they meet the operational definition for clinical pathways developed by
Kinsman et al. (BMC Medicine 8, 2010) and focus on the treatment or management of COPD. All included studies
will be evaluated for risk of bias utilizing methodologies set out by the Cochrane collaboration. Data regarding
patient, professional and systems outcomes will be extracted from all included studies. Data will be presented in
both narrative and tabular form.
Discussion: The systematic review outlined in this protocol aims to identify, assess and synthesise all available
evidence on the effects of CPWs regarding the treatment and management of COPD. As a result, this review will
provide an evidence base for decision makers regarding the practicality, cost effectiveness, patient benefit and
best practices regarding the implementation of CPWs for the care of COPD.
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Integrated care pathways, Care maps
* Correspondence: chris.plishka@usask.ca
1College of Pharmacy and Nutrition, University of Saskatchewan, E3315
Health Sciences Building, Saskatoon SK S7N 5E5, Canada
Full list of author information is available at the end of the article
© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Plishka et al. Systematic Reviews  (2016) 5:135 
DOI 10.1186/s13643-016-0311-8
Background
Description of the condition
Chronic obstructive pulmonary disease (COPD) is a re-
spiratory syndrome characterized by progressive, partially
reversible airway obstruction and lung hyperinflation
[1, 2]. This leads to progressive shortness of breath,
limitation of daily activities and worsening health-
related quality of life, as well as increasingly frequent
and severe exacerbations [1]. It is most often caused by
exposure to tobacco smoke [3], but is also associated
with air pollution and biomass [3] and occupational ex-
posures to dusts and chemicals [3]. The disease is sig-
nificantly underdiagnosed [4, 5], leading to difficulty in
estimating prevalence at both the international and na-
tional level. Estimates for worldwide prevalence of
COPD range from 4 to 20 % [4]. Similar trends can be
seen in Canada where approximately 4 % of Canadians
self-report as being diagnosed [5], but estimates based
on airflow obstruction suggest a prevalence between 12
and 17 % depending on diagnostic criteria [5]. Data
from Europe is less readily available as estimates for
Europe in general are out of date [6]. However, statistics
from the UK also point to underdiagnoses as 1 million
people live with diagnosed COPD while another 2 mil-
lion are undiagnosed [7].
COPD has significant consequences. It is the fourth
leading cause of death in Canada [8] and the third lead-
ing cause of death in the USA. In 2009, COPD caused 8
million physician office visits, 1.5 million ED visits,
715,000 hospitalizations and 133,965 deaths in the USA
[9]. In 2010, costs for COPD in the US were projected to
be $49.9 billion [10]. Exacerbations of COPD (AECOPD)
account for most of the morbidity. In Canada alone,
the cost of moderate and severe exacerbations has been
estimated to be $646–$736 million per year [11]. In the
UK, direct costs of COPD are estimated at £800 million
[12]. In order to minimize the burden of COPD, high-
quality guidelines have been developed [1, 13–16].
These guidelines generally specify disease identification
through spirometry, management through a combin-
ation of smoking cessation, vaccination, pharmacologic
therapy, physical activity, prevention and optimal man-
agement of AECOPD [1, 17]. When implemented,
these steps have shown substantial increases in patient
quality of life, as well as a reduction in healthcare
utilization [18].
Although these results are promising, evidence sug-
gests that the creation of guidelines in isolation is inad-
equate [19–21] as passive dissemination of guidelines
rarely results in meaningful changes in practice [14, 22,
23]. Estimates across the healthcare environment suggest
that 30–40 % of patients do not receive treatments with
proven effectiveness [24], although guideline uptake var-
ies across areas of care [25].
Description of the intervention
One proposed method of minimizing this gap is the im-
plementation of clinical pathways (CPWs). CPWs, also
known as ‘integrated care pathways’, ‘critical pathways’,
‘care plans’ or ‘checklists’, are tools used by health profes-
sionals to guide evidence-based practice and improve
the interaction between health services. They bring the
best available evidence to a range of healthcare profes-
sionals by adapting guidelines to a local context and de-
tailing the essential steps in the assessment and care of
patients [26, 27]. Evidence suggests that CPWs are com-
monly implemented and studied in hospitals [28]. How-
ever, work analyzing the extent of CPW implementation
and evaluation in primary care is still underway [29].
Evidence exists to support the general use of CPWs to
change behaviour and improve quality of care [20, 21,
30–32]. Less evidence is available to establish the effect-
iveness of CPWs for the management of COPD. This is
demonstrated in a previous systematic review focused
on in-hospital management of AECOPD which utilized a
comprehensive search strategy but only identified four
studies which met the inclusion criteria [33]. The system-
atic review described in this protocol follows the preferred
reporting items for systematic review and meta-analysis
(PRISMA) methodology, as outlined in the PRISMA pro-
tocols (PRISMA-P) checklist (see Additional file 1) and
will improve the current knowledge base regarding the de-
velopment and implementation of CPWs for COPD.
Methods
Review questions and objectives
The review will address the following question: What
are the effects of CPWs for COPD on patient, profes-
sional and systems level outcomes. In addition, the
secondary objective of the review is to explore factors
(e.g. implementation strategies, evidence used in devel-
opment) that may explain variation in the effectiveness
of CPWs for COPD.
For the purpose of this review, usual care will be oper-
ationalized as treatment determined at the discretion of
the attending healthcare professional. If studies do not
state that the control group utilizes some form of stan-
dardized care, we will assume the control group utilizes
this definition of usual care.
Criteria for considering studies for this review
The systematic review will include all relevant studies
which address the review questions and objectives. We
will utilize an electronic search strategy to identify all
primary studies reporting on the effectiveness of CPWs
for COPD. We will include studies conducted in both
primary and acute care settings. In addition, we will
include studies focused on COPD maintenance and
AECOPD.
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Types of studies
We will include all primary, quantitative studies which
utilize the following study designs: randomized con-
trolled trials (RCTs), non-randomized controlled trials
(NRCTs), controlled before and after studies (CBA),
interrupted time-series (ITS) studies, cohort (longitu-
dinal) studies and pre-post comparisons. We will not in-
clude editorial reports or studies which do not collect
quantitative data. We will require that all studies include
at least one objective pre-intervention/control group
measure and one objective post-intervention measure or
a measure of change with a corresponding uncertainty
measure. Studies which only include a measure of the
change or fail to report quantitative results will not be
included. We will attempt to contact the study’s author
if it is unclear whether the study meets these criteria.
We will not exclude studies based on methodological
quality; however, study quality will be evaluated using a
risk of bias assessment.
Definition of clinical pathways
In order to ensure we capture all studies utilizing CPWs,
regardless of the terminology used, we will rely on the
operational definition developed by Kinsman et al. [27]
and subsequently refined in the work of Rotter et al. [29]
and Lawal et al. [34]. The definition requires that all in-
cluded studies:
 Utilize a structured multidisciplinary care plan
 Channel the translation of guidelines or evidence
into local structures
 Detail the steps in a course of treatment or care in a
plan, pathway, algorithm, guideline, protocol or
other ‘inventory of actions’ (i.e. the intervention had
time frames or criteria-based progression)
 Aim to standardize care for a specific clinical
problem, procedure or episode of care in a specific
population
Types of participants
Participants will include patients, care providers and
healthcare organizations. All patients with COPD will be
included in the review, regardless of COPD severity,
diagnostic methods or comorbidities. This will ensure
applicability to the care of COPD patients in the ‘real-
life’ clinical setting. Regarding care providers, we will
consider all health professionals, including but not lim-
ited to physicians, nurse practitioners, nurses, physio-
therapists, pharmacists, occupational therapists, social
workers, dietitians and psychologists. Finally, outcomes
regarding healthcare organizations will include all orga-
nizations which provide patient care including hospitals
and primary care facilities.
Types of outcome measures
All objectively reported measures which describe a
patient, professional or systems level outcome will be in-
cluded in the review. Patient outcomes are operational-
ized as outcomes which directly measure the patient’s
health or satisfaction after they leave the system. Profes-
sional outcomes are operationalized as outcomes which
describe how the healthcare professional/staff perceive
their work or how they perform tasks but do not meas-
ure how efficiently this is done. Finally, systems out-
comes are operationalized as outcomes which describe
the ability of the system to perform actions using the
fewest resources possible. These may influence patients’
experiences but they do not describe the health or satis-
faction of the patient following the patient’s visit. There-
fore, system outcomes do not include direct measures of
health (e.g. mortality rate) and or proxy measures of
health (e.g. re-admission rate, infection rate). If studies
report pooled data relating to CPWs for COPD in com-
bination with CPWs for other conditions, then outcomes
will not be extracted unless a subgroup analysis is pre-
sented which shows outcomes for CPWs specific to
COPD care.
Primary outcomes
Objectively measured patient outcomes such as:
 Mortality rate
 Hospital admissions rate
 Emergency department visits
 In-hospital complications rate
 Hospital re-admission rate
 Quality of life
 Patient satisfaction
 Lung function (FEV1/FVC and FEV1)





Objectively defined systems level outcomes such as:
 Length of stay
 Cost
Search strategies
The review will utilize the search hits resulting from
search strategies for a Cochrane Effective Practice and
Organisation of Care (EPOC) systematic review on the
use of CPWs in primary care and a Cochrane EPOC
review update on the use of CPWs in hospitals. These
Plishka et al. Systematic Reviews  (2016) 5:135 Page 3 of 10
search strategies did not utilize any methodological filters.
Search strategies for the review on CPWs in hospitals





 Cochrane Database of Systematic Reviews (Wiley)
 WHO international clinical trials registry platform
 ClinicalTrials.gov
Search strategies for the review on CPWs in primary





 Cochrane Database of Systematic Reviews (OVID)
The search focused on CPWs in primary care was run
from database inception to 2015. The search focused on
CPWs in hospitals was run from 2008 to 2015. Copies
of the search strategies for hospitals and primary care
translated for the MEDLINE database can be found in
Appendices 1 and 2, respectively. Results of these
searches will be imported in EndNote X7, and titles, ab-
stracts and keywords will be searched for the following
terms:
 COPD
 Chronic obstructive pulmonary disease
 Chronic obstructive airways disease
 Chronic obstructive lung disease
 Emphysema
 Chronic bronchitis
In addition to the search results, we will screen the in-
cluded and excluded studies lists of the previously pub-
lished Cochrane systematic review focused on CPWs in
hospitals [28] and any other relevant reviews on CPWs
identified during screening process. In addition, we will
hand search the reference lists for all included studies.
Screening
All titles and abstracts will be imported into a reference
management database and duplicates will be deleted.
Two review authors will independently screen all titles
and abstracts (CP and LA) to assess which studies meet
the inclusion criteria. We will retrieve the full text copies
of all potentially relevant articles, and disagreement re-
garding inclusion will be resolved by a third member of
the research team (TR).
Data extraction
Pairs of two review authors (CP and SF) will independ-
ently extract data according to the double data entry
method by using a standardized data extraction form
developed in Microsoft Access. All data will be ex-
tracted directly from included studies. We will refer
any disagreements to a third review author (TR). If ne-
cessary, we will contact authors of the primary studies
for additional information. Areas of data extraction will
include:
 Study characteristics: publication year, country,
length of follow-up period, urban vs. rural location,
inclusion criteria
 Population characteristics (patient): age, gender,
number of patients, COPD severity
 Population characteristics (professional): types of
healthcare professionals involved, number of
healthcare professionals involved in development,
healthcare setting
 Intervention characteristics: evidence base,
implementation strategy
 Outcomes: patient, professional, systems
Risk of bias assessment
Two authors (CP and SF) will independently assess the
methodological quality of all included studies.
For RCTs, NRCTs and CBA studies, we will use the
criteria suggested by the Cochrane EPOC group to assess
risk of bias in studies with control groups [35]. These
criteria include the following questions:
 Was the allocation sequence adequately generated?
 Was the allocation adequately concealed?
 Were baseline outcome measurements similar?
 Were baseline characteristics similar?
 Were incomplete outcome data adequately
addressed?
 Was knowledge of the allocated interventions
adequately prevented during the study?
 Was the study adequately protected against
contamination?
 Was the study free from selective outcome
reporting?
 Was the study free from other risks of bias?
For ITS studies, we will use the criteria suggested by
the Cochrane EPOC group to assess risk of bias in ITS
studies [35]. These criteria address the following areas:
 Was the intervention independent of other changes?
 Was the shape of the intervention effect pre-specified?
 Was the intervention unlikely to affect data
collection?
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 Was knowledge of the allocated interventions
adequately prevented during the study?
 Were incomplete outcome data adequately
addressed?
 Was the study free from selective outcome
reporting?
 Was the study free from other risks of bias?
For all types of cohort studies not previously mentioned,
we will use the criteria suggested by the Cochrane EPOC
group to assess risk of bias in studies with control groups
[36]. These criteria include the following questions:
 Is confounding of the effect of intervention unlikely
in this study?
 Was selection into the study unrelated to
intervention or unrelated to outcome?
 Do start of follow-up and start of intervention coincide
for most subjects?
 Is intervention status well defined?
 Was information on intervention status recorded at
the time of intervention?
 Was information on intervention status unaffected
by knowledge of the outcome or risk of the
outcome?
 Were the critical co-interventions balanced across
intervention groups?
 Were numbers of switches to other interventions
low?
 Was implementation failure minor?
 Are outcome data reasonably complete?
 Was intervention status reasonably complete for
those in whom it was sought?
 Are data reasonably complete for other variables in
the analysis?
 Was the outcome measure objective?
 Were outcome assessors unaware of the
intervention received by study participants?
 Were the methods of outcome assessment
comparable across intervention groups?
 Were any systematic errors in measurement of the
outcome unrelated to intervention received?
 Is the reported effect estimate unlikely to be selected,
on the basis of the results, from multiple outcome
measurements within the outcome domain?
 Is the reported effect estimate unlikely to be
selected, on the basis of the results, from multiple
analyses of the intervention-outcome relationship?
 Is the reported effect estimate unlikely to be selected,
on the basis of the results, from different subgroups?
We will refer unresolved disagreements regarding risk
of bias to a third author (TR). We will report an appro-
priate judgement for each criterion on each scale and
provide a quote from the study report together with a
justification for our judgment in the risk of bias table.
Based on individual judgements for each domain, we will
provide a summary risk of bias assessment for each
study using the method outlined in the Cochrane Hand-
book which suggests that a study should be rated as low
risk of bias if it is plausible bias is unlikely to seriously
alter the results, unclear risk of bias if bias raises some
doubt about the results and high risk of bias if it is
plausible that bias seriously weakens confidence in re-
sults [37]. We will not exclude studies from the review
based on risk of bias.
Assessment of heterogeneity
We expect variation due to the fact that we include a
range of implementation contexts. However, if there ap-
pears to be a body of studies amenable to meta-analysis,
then we will inspect graphic representations of pooled
results to assess heterogeneity. We will assess statistical
heterogeneity both by visual inspection of forest plots
and by calculating tests of heterogeneity (Chi2 test and
I2 statistic). We will consider an I2 value greater than
60 % to serve as evidence of substantial heterogeneity of
a magnitude where statistical pooling is not appropriate.
Assessment of reporting biases
We will assess potential reporting biases by visual inspec-
tion of funnel plots.
Subgroup analysis
Subgroup analyses will be conducted for all of the primary
and secondary outcomes. We will group studies based on
the following categories:
 Country where the study was carried out
 Evidence base used in the development of CPW
(e.g. international guidelines, literature review)
 Implementation strategy used in the implementation
of the CPW (e.g. passive distribution, face to face
training)
 Year of publication
 Context for which the study was focused (e.g.
hospitals, primary care)
 Disease stage/severity (stage I/mild COPD, stage II/
moderate COPD, stage III/severe COPD and stage
IV/very severe COPD)
Sensitivity analysis
Sensitivity analysis will be carried out to explore the
robustness of the results by investigating the effects of
including and excluding studies with high risk of bias
and studies with missing information. All evidence will
be presented in a standardized summary of findings
(SoF) table.
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Data analysis
We will undertake meta-analyses if we find more than
three studies which report similar outcomes, occur in
similar contexts and do not show statistical heterogen-
eity. Given the fact that there is probably some degree of
heterogeneity, it is likely that a random effects model
will be employed. However, if studies are sufficiently
similar, a fixed effects model will be considered [37].
Data synthesis
We will record and report details on the number of re-
trieved references, the number of duplicates, the number
of full text papers obtained and the number of included
and excluded articles. This information will be reported
based on PRISMA guidelines [38]. The reason for exclu-
sion for all articles for which full text was retrieved will
be included in the review. A synthesis of risk of bias re-
sults will also be presented in tabular form.
Results of meta-analyses will be presented using a for-
est plot. Outcomes of interest will be synthesized in
tabular form and include data for each intervention
group, effects estimates, confidence intervals and statis-
tical significance when available. Financial data will be
presented in US$ for the same base year and will be ad-
justed for inflation by using a country-specific price
index [39]. Subgroup analyses will be presented in a sep-
arate table. In addition, all primary outcomes, meta-
analyses and subgroup analyses will be presented in nar-
rative form taking into account the strength of the evi-
dence and following PRISMA guidelines [40].
Ongoing studies
We will describe identified ongoing studies, where avail-
able, detailing the primary author, research question(s),
methods and outcome measures together with an esti-
mate of the reporting date.
Discussion
Overall, the systematic review outlined in this protocol
aims to identify, assess and synthesise all available evi-
dence on the effects of CPWs regarding the treatment
and management of COPD. As a result, this review will
aim to provide an evidence base for decision makers re-
garding the practicality, cost effectiveness, patient benefit
and best practices regarding the implementation of
CPWs for the care of COPD.
Appendix
Appendix 1: clinical pathways in hospitals search strategy
(MEDLINE translation)
1. Critical Pathways/
2. ((clinical or critical) adj2 (pathway? or path)).ti,ab.
3. ((care adj2 algorithm?) or clinical algorithm?).ti,ab.
4. (care adj2 pathway?).ti,ab.
5. (treatment adj3 algorithm?).ti,ab.
6. (structured care or intensive management).ti,ab.
7. (standardi$ adj3 (treatment? or care or patient care
or plan$)).ti,ab.
8. (care adj2 (plan? or map or maps or protocol? or
algorithm?)).ti,ab.
9. (protocol? adj4 (nursing or treatment or
management or directed or guided)).ti,ab.
10. ((local or locally) adj2 adapt$ adj5
guideline?).ti,ab.
11. (treatment model? adj10 standardi$).ti,ab.
12. (standardi$ adj3 (template or templates)).ti,ab.
13. or/1-12 [Pathways]
14. Clinical protocols/
15. Algorithm/and (di.fs. or (treatment or care or
patient?).ti. or diagnos$.ti,ab.)
16. Practice Guidelines as Topic/or Guideline
Adherence/or Guidelines as topic/
17. ((guideline or guidelines) adj2 (adher$ or
implement$)).ti,ab.
18. (guideline? adj4 (compliance or complying)).ti,ab.
19. or/16-18 [PGL or GL Adherence]
20. (adherence or care or compliance or comply$ or
implement$ or impact or plan? or standardi?ed
or pathway or (treatment adj3 (protocol? or
algorithm?))).ti,ab.
21. 19 and 20 [GL]
22. *Guidelines as topic/or *Practice Guidelines as topic/
23. *Guideline Adherence/
24. or/22-23 [Focussed MeSH Guideline]
25. Primary health care/or Primary Care Nursing/
26. Family practice/or General Practice/
27. General Practitioners/or Physicians, Family/or
Physicians, Primary Care/
28. ((general or family) adj2 (practice? or practitioner?
or physician? or doctor?)).ti,ab.
29. (primary adj2 (care or health care or healthcare or
medical care or patient care)).ti,ab.
30. (primary care or family medic$ or general practice
or family practi$).jn.
31. GP.ti.
32. or/25-31 [Primary Care]
33. Ambulatory Care/or Community medicine/or
community health nursing/or community health
services/or home care services/or Community
mental health services/or Community Pharmacy
Services/
34. Ambulatory Care Facilities/or Community Health
Centers/
35. (community or communities).ti,ab,hw.
36. (((ambulatory or walk-in or neighbo?rhood or
community) adj2 (clinic? or care centre or care
centres or care center? or health$ centre or
Plishka et al. Systematic Reviews  (2016) 5:135 Page 6 of 10
health$ centres or health$ center?)) or public
clinic?).ti,ab.
37. ((urban or rural) adj3 health).ti,ab.
38. or/33-37 [Community Care]
39. 13 and 32 [Pathway terms & PC]
40. (and/13,38) not 39 [Pathways & Community-
Ambulatory Care]
41. (and/24,32) not (or/39-40) [Focussed GL & PC]
42. (and/24,38) not (or/39-41) [Focussed GL &
Community-Ambulatory Care]
43. (21 and (or/32,38)) not (or/39-42) [GL & PC/Amb
Care]
44. ((or/14-15) and ((or/26-31,38) or *Primary health
care/or *Primary Care Nursing/)) not (or/39-43)
[Clinical Protocols/Algorithms Mesh & PC/
Community Care-combine with RCT filter only]
45. (randomized controlled trial or controlled clinical
trial).pt. or randomized.ab. or placebo.ab. or clinical
trials as topic.sh. or randomly.ab. or trial.ti.
46. exp animals/not humans.sh.
47. 45 not 46 [Cochrane RCT Filter 6.4.d Sens/Precision
Maximizing]
48. intervention?.ti. or (intervention? adj6 (clinician? or
collaborat$ or community or complex or DESIGN$
or doctor? or educational or family doctor? or family
physician? or family practitioner? or financial or GP
or general practice? or hospital? or impact? or
improv$ or individuali?e? or individuali?ing or
interdisciplin$ or multicomponent or multi-
component or multidisciplin$ or multi-disciplin$ or
multifacet$ or multi-facet$ or multimodal$ or multi-
modal$ or personali?e? or personali?ing or pharma-
cies or pharmacist? or pharmacy or physician? or
practitioner? or prescrib$ or prescription? or pri-
mary care or professional$ or provider? or regulatory
or regulatory or tailor$ or target$ or team$ or usual
care)).ab.
49. (pre-intervention? or preintervention? or “pre
intervention?” or post-intervention? or postintervention?
or “post intervention?”).ti,ab. [added 2.4]
50. (hospital$ or patient?).hw. and (study or studies or
care or health$ or practitioner? or provider? or
physician? or nurse? or nursing or doctor?).ti,hw.
51. demonstration project?.ti,ab.
52. (pre-post or “pre test$” or pretest$ or posttest$ or
“post test$” or (pre adj5 post)).ti,ab.
53. (pre-workshop or post-workshop or (before adj3
workshop) or (after adj3 workshop)).ti,ab.
54. trial.ti. or ((study adj3 aim?) or “our study”).ab.
55. (before adj10 (after or during)).ti,ab.
56. (“quasi-experiment$” or quasiexperiment$ or “quasi
random$” or quasirandom$ or “quasi control$” or
quasicontrol$ or ((quasi$ or experimental) adj3
(method$ or study or trial or design$))).ti,ab,hw.
57. (“time series” adj2 interrupt$).ti,ab,hw.
58. (time points adj3 (over or multiple or three or four or
five or six or seven or eight or nine or ten or eleven or
twelve or month$ or hour? or day? or “more than”)).ab.
59. pilot.ti.
60. Pilot projects/
61. (clinical trial or controlled clinical trial or
multicenter study).pt.
62. (multicentre or multicenter or multi-centre or
multi-center).ti.
63. random$.ti,ab. or controlled.ti.
64. (control adj3 (area or cohort? or compare? or
condition or design or group? or intervention? or
participant? or study)).ab. not (controlled clinical
trial or randomized controlled trial).pt.
65. evaluation studies as topic/or prospective studies/or
retrospective studies/[Added Jan 2013]
66. (utili?ation or programme or programmes).ti.
[Added Jan 2013]
67. (during adj5 period).ti,ab. [Added Jan 2013]
68. ((strategy or strategies) adj2 (improv$ or
education$)).ti,ab. [Added Jan 2013]
69. “comment on”.cm. or review.pt. or (review not “peer
review$”).ti. or randomized controlled trial.pt.
[Changed Jan 2013]
70. (rat or rats or cow or cows or chicken? or horse or
horses or mice or mouse or bovine or animal?).ti.
71. exp animals/not humans.sh.
72. (or/48-68) not (or/69-71) [EPOC Methods Filter
2.5-added Evaluation Studies line forward–Jan
20130 Medline]
73. (or/39-44) and 47 [RCT Results]
74. (39 and 72) not 73 [EPOC Filter Results Set 1 :
Pathways & PC]
75. (40 and 72) not (or/73-74) [EPOC Filter Set 2:
Pathways & Community-Ambulatory Care]
76. (41 and 72) not (or/73-75) [EPOC Filter Set 3:
Focussed GL & PC]
77. (42 and 72) not (or/73-76) [EPOC Filter Set 4:
Focussed GL & Ambultory]
78. (43 and 72) not (or/73-77) [EPOC Filter Set 5: GL &
PC/Amb care]
79. or/74-78 [EPOC Filter Results]
80. 73 or 79
Appendix 2: clinical pathways in primary care search
strategy (MEDLINE translation)
1. Evoked Potentials, Somatosensory/(11114)
2. Critical Pathways/(4597)
3. ((clinical or critical) adj2 (pathway? or path)).ti,ab.
(6415)
4. (care adj2 algorithm?) or clinical algorithm?).ti,ab.
(1016)
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5. (care adj2 pathway?).ti,ab. (2078)
6. (treatment adj3 algorithm?).ti,ab. (4585)
7. (structured care or intensive management).ti,ab. (743)
8. (standardi$ adj3 (treatment? or care or patient care
or plan$)).ti,ab. (4945)
9. (care adj2 (plan? or map or maps or protocol? or
algorithm?)).ti,ab. (9151)
10. (protocol? adj4 (nursing or treatment or
management or directed or guided)).ti,ab. (21924)
11. ((local or locally) adj2 adapt$ adj5 guideline?).ti,ab.
(70)
12. (treatment model? adj10 standardi$).ti,ab. (8)
13. (standardi$ adj3 (template or templates)).ti,ab. (210)
14. or/2-13 [Pathways] (51371)
15. Clinical protocols/(19906)
16. Algorithm/and (di.fs. or (treatment or care or
patient?).ti. or diagnos$.ti,ab.) (38867)
17. Practice Guidelines as Topic/or Guideline
Adherence/or Guidelines as topic/(122045)
18. ((guideline or guidelines) adj2 (adher$ or
implement$)).ti,ab. (4692)
19. (guideline? adj4 (compliance or complying)).ti,ab.
(2523)
20. or/17-19 [PGL or GL Adherence] (124948)
21. (adherence or care or compliance or comply$ or
implement$ or impact or plan? or standardi?ed or
pathway or (treatment adj3 (protocol? or
algorithm?))).ti,ab. (2441299)
22. 20 and 21 [GL] (47061)
23. *Guidelines as topic/or *Practice Guidelines as topic/
(34513)
24. *Guideline Adherence/(9488)
25. or/23-24 [Focussed MeSH Guideline] (41286)
26. Primary health care/or Primary Care Nursing/
(54165)
27. Family practice/or General Practice/(63815)
28. General Practitioners/or Physicians, Family/or
Physicians, Primary Care/(17793)
29. ((general or family) adj2 (practice? or practitioner?
or physician? or doctor?)).ti,ab. (91238)
30. (primary adj2 (care or health care or healthcare or
medical care or patient care)).ti,ab. (87195)
31. (primary care or family medic$ or general practice
or family practi$).jn. (8099)
32. GP.ti. (3130)
33. or/26-32 [Primary Care] (213442)
34. Ambulatory Care/or Community medicine/or
community health nursing/or community health
services/or home care services/or Community
mental health services/or Community Pharmacy
Services/(121247)
35. Ambulatory Care Facilities/or Community Health
Centers/(17729)
36. (community or communities).ti,ab,hw. (390492)
37. (((ambulatory or walk-in or neighbo?rhood or
community) adj2 (clinic? or care centre or care
centres or care center? or health$ centre or
health$ centres or health$ center?)) or public
clinic?).ti,ab. (9467)
38. ((urban or rural) adj3 health).ti,ab. (10234)
39. or/34-38 [Community Care] (460698)
40. 14 and 33 [Pathway terms & PC] (2674)
41. (and/14,39) not 40 [Pathways & Community-
Ambulatory Care] (3006)
42. (and/25,33) not (or/40-41) [Focussed GL & PC] (3031)
43. (and/25,39) not (or/40-42) [Focussed GL &
Community-Ambulatory Care] (1998)
44. (22 and (or/33,39)) not (or/40-43) [GL & PC/Amb
Care] (6172)
45. ((or/15-16) and ((or/27-32,39) or *Primary health
care/or *Primary Care Nursing/)) not (or/40-44)
[Clinical Protocols/Algorithms Mesh & PC/
Community Care-combine with RCT filter only]
(3119)
46. (randomized controlled trial or controlled clinical
trial).pt. or randomized.ab. or placebo.ab. or clinical
trials as topic.sh. or randomly.ab. or trial.ti. (906690)
47. exp animals/not humans.sh. (3947170)
48. 46 not 47 [Cochrane RCT Filter 6.4.d Sens/Precision
Maximizing] (836655)
49. intervention?.ti. or (intervention? adj6 (clinician? or
collaborat$ or community or complex or DESIGN$
or doctor? or educational or family doctor? or
family physician? or family practitioner? or financial
or GP or general practice? or hospital? or impact?
or improv$ or individuali?e? or individuali?ing or
interdisciplin$ or multicomponent or multi-
component or multidisciplin$ or multi-disciplin$
or multifacet$ or multi-facet$ or multimodal$ or
multi-modal$ or personali?e? or personali?ing or
pharmacies or pharmacist? or pharmacy or phys-
ician? or practitioner? or prescrib$ or prescription?
or primary care or professional$ or provider? or
regulatory or regulatory or tailor$ or target$ or
team$ or usual care)).ab. (163136)
50. (pre-intervention? or preintervention? or “pre
intervention?” or post-intervention? or
postintervention? or “post intervention?”).ti,ab.
[added 2.4] (10329)
51. (hospital$ or patient?).hw. and (study or studies or
care or health$ or practitioner? or provider? or
physician? or nurse? or nursing or doctor?).ti,hw.
(720195)
52. demonstration project?.ti,ab. (1958)
53. (pre-post or “pre test$” or pretest$ or posttest$
or “post test$” or (pre adj5 post)).ti,ab. (66138)
54. (pre-workshop or post-workshop or (before adj3
workshop) or (after adj3 workshop)).ti,ab. (617)
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55. trial.ti. or ((study adj3 aim?) or “our study”).ab.
(634701)
56. (before adj10 (after or during)).ti,ab. (358281)
57. (“quasi-experiment$” or quasiexperiment$ or “quasi
random$” or quasirandom$ or “quasi control$” or
quasicontrol$ or ((quasi$ or experimental) adj3
(method$ or study or trial or design$))).ti,ab,hw.
(101852)
58. (“time series” adj2 interrupt$).ti,ab,hw. (1067)
59. (time points adj3 (over or multiple or three or four or
five or six or seven or eight or nine or ten or eleven or




62. (clinical trial or controlled clinical trial or
multicenter study).pt. (627959)
63. (multicentre or multicenter or multi-centre or
multi-center).ti. (29139)
64. random$.ti,ab. or controlled.ti. (759522)
65. (control adj3 (area or cohort? or compare? or
condition or design or group? or intervention? or
participant? or study)).ab. not (controlled clinical
trial or randomized controlled trial).pt. (412029)
66. evaluation studies as topic/or prospective studies/or
retrospective studies/[Added Jan 2013] (958573)
67. (utili?ation or programme or programmes).ti.
[Added Jan 2013] (54870)
68. (during adj5 period).ti,ab. [Added Jan 2013] (300309)
69. ((strategy or strategies) adj2 (improv$ or
education$)).ti,ab. [Added Jan 2013] (18447)
70. “comment on”.cm. or review.pt. or (review not “peer
review$”).ti. or randomized controlled trial.pt.
[Changed Jan 2013] (2926583)
71. (rat or rats or cow or cows or chicken? or horse or
horses or mice or mouse or bovine or animal?).ti.
(1343855)
72. exp animals/not humans.sh. (3947170)
73. (or/49-69) not (or/70-72) [EPOC Methods Filter 2.5-
added Evaluation Studies line forward–Jan 20130
Medline] (2833476)
74. (or/40-45) and 48 [RCT Results] (2611)
75. (40 and 73) not 74 [EPOC Filter Results Set 1:
Pathways & PC] (1116)
76. (41 and 73) not (or/74-75) [EPOC Filter Set 2:
Pathways & Community-Ambulatory Care] (1416)
77. (42 and 73) not (or/74-76) [EPOC Filter Set 3:
Focussed GL & PC] (985)
78. (43 and 73) not (or/74-77) [EPOC Filter Set 4:
Focussed GL & Ambultory] (739)
79. (44 and 73) not (or/74-78) [EPOC Filter Set 5: GL &
PC/Amb care] (2295)
80. or/75-79 [EPOC Filter Results] (6551)
81. 74 or 80
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